Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that a high frequency of androgenetic alopecia is associated with increased severity of COVID-19 in hospitalized patients.

This study found that patients with alopecia areata had higher levels of ESR, CRP, and mean platelet volume compared to controls, and that these markers, along with the neutrophils to lymphocytes ratio, were associated with increased disease severity.

This narrative review found a strong association between oxidative stress and the severity of alopecia areata, noting that increased oxidant and reduced antioxidant biomarkers correlate with higher disease severity scores, and emphasizes the need for larger prospective studies for clinical validation.

In this case-control study, EGF levels were significantly higher in patients with alopecia areata than in healthy controls, and these elevated levels positively correlated with the severity and extent of the disease, suggesting EGF as a potential marker for alopecia areata severity.

In this phase 3 trial analysis, baricitinib improved scalp hair growth in adults with severe alopecia areata, with a faster and higher response in those receiving 4 mg compared to 2 mg, but response varied with severity at baseline and continued through week 52.

This study found that higher serum IL-21 levels may serve as a promising diagnostic and prognostic marker for alopecia areata, strongly correlating with disease activity.

This study observed that PD-1+CXCR5-CD4+T peripheral helper cells are significantly elevated in patients with systemic lupus erythematosus and are correlated with disease activity indicators, suggesting their potential role in lupus pathogenesis.

This study observed a significant increase in cellular retinol-binding protein-1 expression in lesional skin of patients with alopecia areata compared to healthy controls, suggesting its potential role in the disease's pathogenesis.

In this study, dutasteride more effectively reduced prostate cancer cell viability than finasteride in vitro, but did not significantly alter the angiogenic response.

This study found that serum androgen levels were associated with the severity of hirsutism in women, with significantly higher levels observed in those with moderate to severe hair growth.

This case report suggests that individualized homeopathic therapy with Carcinosin may benefit pediatric patients with alopecia areata by improving hair regrowth and psychological symptoms, as supported by standardized assessment tools.

This study found that, among patients in Ismailia, Egypt, patchy alopecia areata was the most common form, with a significant positive correlation between the number of lesions and disease severity, and noted males predominantly affected by this condition.

This study found that patients with alopecia areata had significantly lower serum 25-Hydroxy vitamin D levels compared to healthy controls, and observed a significant inverse relationship between vitamin D levels and disease severity.

This study found that long-term dutasteride therapy in men with benign prostatic hyperplasia worsened erectile dysfunction, reduced testosterone levels, and increased blood glucose and lipid profile, indicating negative metabolic impacts.

The authors propose that higher testosterone levels in hospitalized COVID-19 patients might be associated with worse outcomes.

This study found that patients with alopecia areata had a significantly higher mean platelet volume compared to healthy individuals, suggesting a potential link between hematological markers and the severity of the disease.

This study found that alopecia areata was associated with increased serum levels of retinol-binding protein-4 compared to controls, but no correlation with disease severity was observed.

This study surveyed dermatologists in Greece and Italy and found significant variability and challenges in the diagnosis and treatment of alopecia areata, including limited use of severity scores and diverse treatment approaches, particularly for special site involvement and chronic cases.

This consensus provides a framework for standardized diagnosis and treatment of alopecia areata in the Asia Pacific region, recommending specific therapies based on age and disease severity.

This study observed that oral tofacitinib was effective and safe for treating alopecia areata in paediatric patients, with 82% of pre-adolescent participants experiencing hair regrowth and 64% showing significant improvement in their hair loss severity scores.

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.

In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.

This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.

This letter discusses the limited treatment options for pediatric alopecia areata and the lack of controlled studies for therapies like systemic and off-label immunosuppressive drugs, without reporting new clinical results.

This case series found that oral tofacitinib treatment in eight adolescents with alopecia universalis led to significant regrowth of hair, though relapse is likely after stopping therapy.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

This review presents standardized methods for assessing and tracking hair loss in alopecia areata but reports no clinical results, with the authors noting time limitations in clinical practice.

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.